Summary:
MUMBAI, India, Sept.
21, 2021 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd.
(Glenmark) has received final approval by the United States Food & Drug Administration (U.S.
FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc.
According to IQVIATM sales data for the 12 month period ending July 2021, the Evoclin® Foam, 1%, market2 achieved annual sales of approximately $12.0 million*.
Glenmark"s current portfolio consists of 173 products authorized for distribution in the U.S.